Overview
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
Status:
Completed
Completed
Trial end date:
2009-05-01
2009-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Incyte Corporation
Criteria
Inclusion Criteria:- Subjects must have psoriatic lesions measuring protocol specific BSA
Exclusion Criteria:
- Lesions solely involving the palms of the hands, the soles of the feet, the
intertriginious areas, the scalp or the face
- Pustular psoriasis or erythroderma